Search - tctmd.com

Displaying 1 - 20 of 29

Sort: Relevancy | Date

Reimbursement Issues Seem to Be Holding Renal Denervation Back

News Features

Reimbursement Issues Seem to Be Holding Renal Denervation Back

December 19, 2024

Initial US Commercial TriClip Cases Offer Hope, but Reimbursement Still a Big Question

News Features

Initial US Commercial TriClip Cases Offer Hope, but Reimbursement Still a Big Question

August 09, 2024

The Promise of Pulsed-Field Ablation: Cautious Optimism Amid Some Unknowns

News Features

The Promise of Pulsed-Field Ablation: Cautious Optimism Amid Some Unknowns

March 29, 2024

FDA Clears AI-ECG Screening Tools for CV Care: What’s Next Is Up for Grabs

News Features

FDA Clears AI-ECG Screening Tools for CV Care: What’s Next Is Up for Grabs

Yael L. Maxwell

December 14, 2023

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

News Features

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

May 12, 2023

Myriad Novel Devices Aim to Boost Decongestion in Acute HF

News Features

Myriad Novel Devices Aim to Boost Decongestion in Acute HF

April 10, 2023

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

Expired Cardiac Devices May Do Global Good, but Safety Unknown

News Features

Expired Cardiac Devices May Do Global Good, but Safety Unknown

Yael L. Maxwell

August 26, 2021

Funding the Future: How Industry Support for CV Trials Could Evolve

News Features

Funding the Future: How Industry Support for CV Trials Could Evolve

Michael O'Riordan

December 17, 2020

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

Year in Review: DAPA-HF Tops Heart Failure News Amid Other Wins and Losses

News Features

Year in Review: DAPA-HF Tops Heart Failure News Amid Other Wins and Losses

December 23, 2019

Year in Review: Low-Risk TAVR Trials Big in 2019, but QoL Data Impresses, Too

News Features

Year in Review: Low-Risk TAVR Trials Big in 2019, but QoL Data Impresses, Too

Michael O'Riordan

December 18, 2019

Year in Review: Payment Fights, Wearables, Burnout Defined Cardiology Practice in 2019

News Features

Year in Review: Payment Fights, Wearables, Burnout Defined Cardiology Practice in 2019

December 17, 2019

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

News Features

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Michael O'Riordan

February 01, 2019

Top News in Endovascular Therapy: 2018

News Features

Top News in Endovascular Therapy: 2018

December 28, 2018

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

News Features

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

October 22, 2018

To RCT or Not to RCT? Impella Debate Pivots on How Best to Study Patients on the Brink of Death

News Features

To RCT or Not to RCT? Impella Debate Pivots on How Best to Study Patients on the Brink of Death

May 02, 2018

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

News Features

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

September 15, 2017

Catheter Kerfuffle: How Concerning Is Off-Label Use in Stroke Interventions?

News Features

Catheter Kerfuffle: How Concerning Is Off-Label Use in Stroke Interventions?

June 21, 2017

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

News Features

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

Michael O'Riordan

May 08, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.